Nothing Special   »   [go: up one dir, main page]

Melcher et al., 2014 - Google Patents

Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus

Melcher et al., 2014

View PDF
Document ID
3093429511285974800
Author
Melcher R
Willmon C
Diaz R
Zaidi S
Coffey M
Selby P
Harrington K
Pandha H
Melcher A
Publication year

External Links

Snippet

Optimum clinical protocols require systemic delivery of oncolytic viruses in the presence of an intact immune system. We have shown that pre-conditioning with immune modulators, or loading virus onto carrier cells ex vivo, enhances virus-mediated anti-tumor activity. Our …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Ilett et al. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus
Hammerich et al. In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf
AU2015342790B2 (en) Cancer immunotherapy using virus particles
Antony et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
Wongthida et al. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus
Wachowska et al. 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy
AU2016294602A1 (en) Compositions and methods for treating peritoneal cancers
De Lucia et al. Retargeted and multi-cytokine-armed herpes virus is a potent cancer endovaccine for local and systemic anti-tumor treatment
JP2019500055A (en) Modified immune cells and uses thereof
O’Reilly et al. Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation
Melcher et al. Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus
Melcher et al. Accepted m
EA015510B1 (en) Method for enhancing the amount of mononuclear cells in a subject suffering from cancer, and pharmaceutical combination used therefor
JP2023554319A (en) Methods and materials for treating cancer
Cressent et al. Interleukin-2 and interleukin-4 display potent antitumour activity on rat medullary thyroid carcinoma cells
US20220133869A1 (en) Breast cancer tumor cell vaccines
Ho Efficacy and Mechanism of Action of CD40 Ligand and Interleukin-12 Plasmid Electroporation Intratumoral Immunotherapy
Hammerich et al. Immunomodulation within a single tumor site to induce systemic antitumor immunity: in situ vaccination for cancer
Komant et al. Oncolytic vaccinia virus as a precision cancer vaccine platform
Biller et al. The powerful ability of the immune system to recog-nize and eliminate cancer, based on exquisitely subtle differences between normal and malignant cells, is the fundamental rationale for the immunotherapy of cancer. Many lines of evidence support a role for the immune system in controlling cancer. These include (1) the occurrence of spontaneous remissions in cancer patients without treatment,(2) the increased incidence of some types of cancer in immunosuppressed patients
JP2024529429A (en) Cancer vaccines based on induced pluripotent stem cells
Bash et al. Vaccinia virus oncolysates in the treatment of malignant melanoma
Rakic Oncolytic Vesicular Stomatitis Virus and Sunitinib Combination Therapy for Treating Neuroblastoma
McKechnie et al. Vaccination and malignant disease: Promising therapeutic approach
Wongthida Understanding, and exploiting, the contribution of the immune system to the therapeutic efficacy of oncolytic virotherapy with vesicular stomatitis virus (VSV)